CANCER:

Hepatocellular Cancer

EGFR overexpression EGFR overexpression	Hepatocellular Cancer HCC	gefitinib + lenvatinib Sensitive: C3 – Early Trials Nature - 1 week
No biomarker No biomarker	Hepatocellular Cancer HCC	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	bevacizumab + atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	cabozantinib tablet Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
AFP elevation AFP elevation	Hepatocellular Cancer HCC	ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	regorafenib Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	lenvatinib Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	sorafenib Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	nivolumab + ipilimumab Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	tislelizumab Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	nivolumab Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Hepatocellular Cancer HCC	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Hepatocellular Cancer HCC	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Hepatocellular Cancer HCC	larotrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Hepatocellular Cancer HCC	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Hepatocellular Cancer HCC	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Hepatocellular Cancer HCC	entrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Hepatocellular Cancer HCC	Sensitive: A2 - Guideline
AFP elevation AFP elevation	Hepatocellular Cancer HCC	regorafenib Sensitive: B - Late Trials
FGF21-H FGF21-H	Hepatocellular Cancer HCC	lenvatinib Sensitive: B - Late Trials
No biomarker No biomarker	Hepatocellular Cancer HCC	SRF388 Sensitive: B - Late Trials
HGF-H + VEGFA-H HGF-H + VEGFA-H	Hepatocellular Cancer HCC	erlotinib + sorafenib Resistant: B - Late Trials
VEGFA-H VEGFA-H	Hepatocellular Cancer HCC	lenvatinib Resistant: B - Late Trials
FGFR2 fusion FGFR2 fusion	Hepatocellular Cancer HCC	infigratinib Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Hepatocellular Cancer HCC	lenvatinib Sensitive: C2 – Inclusion Criteria
AFP elevation AFP elevation	Hepatocellular Cancer HCC	sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria
TSC2 overexpression TSC2 overexpression	Hepatocellular Cancer HCC	everolimus Resistant: C3 – Early Trials
FOXA3 overexpression FOXA3 overexpression	Hepatocellular Cancer HCC	sorafenib Sensitive: C3 – Early Trials
CXCL12-H CXCL12-H	Hepatocellular Cancer HCC	T-lymphocyte cell therapy Sensitive: C3 – Early Trials
KDR-H KDR-H	Hepatocellular Cancer HCC	T-lymphocyte cell therapy Sensitive: C3 – Early Trials
VEGFA-H VEGFA-H	Hepatocellular Cancer HCC	T-lymphocyte cell therapy Sensitive: C3 – Early Trials
ST6GAL1 elevation ST6GAL1 elevation	Hepatocellular Cancer HCC	lenvatinib Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Hepatocellular Cancer HCC	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Hepatocellular Cancer HCC	PD1 inhibitor Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Hepatocellular Cancer HCC	tislelizumab Sensitive: C3 – Early Trials
GPC3 overexpression GPC3 overexpression	Hepatocellular Cancer HCC	atezolizumab + RG7686 Sensitive: C3 – Early Trials
AFP elevation AFP elevation	Hepatocellular Cancer HCC	cabozantinib tablet Sensitive: C3 – Early Trials
ANGPT2-H ANGPT2-H	Hepatocellular Cancer HCC	sorafenib Sensitive: C3 – Early Trials
FGF19-H FGF19-H	Hepatocellular Cancer HCC	sorafenib Sensitive: C3 – Early Trials
FGF19-L FGF19-L	Hepatocellular Cancer HCC	lenvatinib Sensitive: C3 – Early Trials
ANGPT2-L ANGPT2-L	Hepatocellular Cancer HCC	lenvatinib Sensitive: C3 – Early Trials
FGFR4 G388R + NOS3 rs2070744 FGFR4 G388R + NOS3 rs2070744	Hepatocellular Cancer HCC	lenvatinib Sensitive: C3 – Early Trials
miR-216a-3p overexpression miR-216a-3p overexpression	Hepatocellular Cancer HCC	sorafenib Sensitive: C3 – Early Trials
HES1 overexpression HES1 overexpression	Hepatocellular Cancer HCC	bevacizumab + atezolizumab Resistant: C3 – Early Trials
Tregs-H Tregs-H	Hepatocellular Cancer HCC	bevacizumab + atezolizumab Sensitive: C3 – Early Trials
KDR overexpression KDR overexpression	Hepatocellular Cancer HCC	bevacizumab + atezolizumab Sensitive: C3 – Early Trials
PAK4 deletion PAK4 deletion	Hepatocellular Cancer HCC	Immunotherapy Sensitive: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Hepatocellular Cancer HCC	Immunotherapy Sensitive: C3 – Early Trials
Chr amplification(11)(q23) Chr amplification(11)(q23)	Hepatocellular Cancer HCC	Immunotherapy Sensitive: C3 – Early Trials
HOXC8 overexpression HOXC8 overexpression	Hepatocellular Cancer HCC	oxaliplatin Sensitive: C3 – Early Trials
ATP5IF1 overexpression ATP5IF1 overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: C3 – Early Trials
PI16 overexpression PI16 overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: C3 – Early Trials
TGFB1 elevation TGFB1 elevation	Hepatocellular Cancer HCC	sorafenib + LY2157299 Sensitive: C3 – Early Trials
VEGFA elevation VEGFA elevation	Hepatocellular Cancer HCC	sunitinib Sensitive: C3 – Early Trials
KRAS G13D KRAS G13D	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
KRAS Q61H KRAS Q61H	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
KRAS A146T KRAS A146T	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
KRAS G12V KRAS G12V	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
KRAS G12S KRAS G12S	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
KRAS G12R KRAS G12R	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
KRAS G12D KRAS G12D	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
KRAS G12C KRAS G12C	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
KRAS G12A KRAS G12A	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
NRAS Q61R NRAS Q61R	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
NRAS Q61L NRAS Q61L	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
NRAS Q61K NRAS Q61K	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
NRAS Q61H NRAS Q61H	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
FGF19 positive FGF19 positive	Hepatocellular Cancer HCC	BLU-554 Sensitive: C3 – Early Trials
FGF19 negative FGF19 negative	Hepatocellular Cancer HCC	BLU-554 Resistant: C3 – Early Trials
FGF19 overexpression FGF19 overexpression	Hepatocellular Cancer HCC	BLU-554 Sensitive: C3 – Early Trials
FGF4 amplification FGF4 amplification	Hepatocellular Cancer HCC	sorafenib Sensitive: C3 – Early Trials
FGF3 amplification FGF3 amplification	Hepatocellular Cancer HCC	sorafenib Sensitive: C3 – Early Trials
ADAM9 underexpression ADAM9 underexpression	Hepatocellular Cancer HCC	nivolumab Sensitive: C3 – Early Trials
TGFB1-H TGFB1-H	Hepatocellular Cancer HCC	pembrolizumab Sensitive: C3 – Early Trials
AFP elevation AFP elevation	Hepatocellular Cancer HCC	sorafenib Sensitive: C3 – Early Trials
CD133 overexpression CD133 overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: C3 – Early Trials
THY1 overexpression THY1 overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: C3 – Early Trials
EFNB2 negative EFNB2 negative	Hepatocellular Cancer HCC	sEphB4-HSA Sensitive: C3 – Early Trials
EFNB2 positive EFNB2 positive	Hepatocellular Cancer HCC	sEphB4-HSA Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Hepatocellular Cancer HCC	SNG-162 Sensitive: C3 – Early Trials
S100A16 overexpression S100A16 overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: C3 – Early Trials
S100A8 overexpression S100A8 overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: C3 – Early Trials
KPNA3 underexpression KPNA3 underexpression	Hepatocellular Cancer HCC	sorafenib Sensitive: C3 – Early Trials
PCSK9 underexpression PCSK9 underexpression	Hepatocellular Cancer HCC	Immunotherapy Sensitive: C3 – Early Trials
NFE2L2 overexpression NFE2L2 overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: C3 – Early Trials
MET overexpression MET overexpression	Hepatocellular Cancer HCC	tepotinib Sensitive: C3 – Early Trials
ASS1 negative ASS1 negative	Hepatocellular Cancer HCC	BCT-100 Sensitive: C3 – Early Trials
KMT2C mutation KMT2C mutation	Hepatocellular Cancer HCC	PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials
DDR DDR	Hepatocellular Cancer HCC	FOLFOX Sensitive: C3 – Early Trials
GPC3 positive GPC3 positive	Hepatocellular Cancer HCC	CAR-T immunotherapy Sensitive: C3 – Early Trials
FGF19 positive FGF19 positive	Hepatocellular Cancer HCC	H3B-6527 Sensitive: C3 – Early Trials
ANGPT2-L ANGPT2-L	Hepatocellular Cancer HCC	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials

Hepatocellular Cancer

Associations(156)

Associations
(156)